中文名稱: 兔抗NFKB1 (Phospho-Ser337)多克隆抗體
英文名稱: Anti-NFKB1 (Phospho-Ser337) rabbit polyclonal antibody
別 名: p50; KBF1; p105; EBP-1; NF-kB1; NFKB-p50; NFkappaB; NF-kappaB; NFKB-p105; NF-kappa-B
相關(guān)類別: 一抗
儲 存: 冷凍(-20℃) 避光
宿 主: Rabbit
抗 原: NFKB1 (Phospho-Ser337)
反應(yīng)種屬: Human, Mouse, Rat
標(biāo) 記 物: Unconjugate
克隆類型: rabbit polyclonal
技術(shù)規(guī)格
Background: |
NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor, but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function, although processing of NFKB1/p105 also appears to occur post-translationally. p50 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. In a complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPK signaling; active MAP3K8 is released by proteasome-dependent degradation of NFKB1/p105. |
Applications: |
WB, IHC, IF |
Name of antibody: |
NFKB1 (Phospho-Ser337) |
Immunogen: |
Synthetic peptide of human NFKB1 (Phospho-Ser337) |
Full name: |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (Phospho-Ser337) |
Synonyms: |
p50; KBF1; p105; EBP-1; NF-kB1; NFKB-p50; NFkappaB; NF-kappaB; NFKB-p105; NF-kappa-B |
SwissProt: |
P19838 |
IHC positive control: |
Human breast carcinoma |
IHC Recommend dilution: |
50-100 |
WB Predicted band size: |
50 kDa; 120 kDa |
WB Positive control: |
HeLa cells |
WB Recommended dilution: |
500-1000 |
IF Positive control: |
HeLa cells |
IF Recommended dilution |
100-200 |